



Drug Formulary Update, October 2016 Medicare

Updates to the HealthPartners Medicare Drug Formulary are listed below.

Please see www.healthpartners.com/formularies for details.

Drug Name	Current Status	New Status	Effective Date	Comments
Cabometyx	NF	T5 PA	5/7/2016	Cabozantinib (Cabometyx), an oral tablet for renal cell carcinoma, has updated prior authorization criteria.
Nuplazid	NF	T5 PA	7/2/2016	Pimavanserin (Nuplazid), an oral tablet for hallucinations and delusions associated with Parkinson's disease psychosis, requires prior authorization.
Tecentriq	NF	T5 PA	7/2/2016	See web for prior authorization criteria
Briviact	NF	T5 PA	7/2/2016	Brivaracetam (Briviact), a new oral seizure medication, requires prior authorization.
Trintellix	NF	T4 PA	7/2/2016	See web for prior authorization criteria
Spritam	NF	T3 PA	7/9/2016	See web for prior authorization criteria
Epclusa	NF	T5 PA	10/1/2016	See web for prior authorization criteria
famciclovir	NF	T2	10/1/2016	Famciclovir (generic Famvir), a low cost generic antiviral medication, has been added to the formulary.
ibandronate	NF	T2	10/1/2016	Ibandronate (generic Boniva), a low cost generic osteoporosis medication, has been added to the formulary.
rosuvastatin	NF	T2	10/1/2016	Rosuvastatin (generic Crestor) has been added to formulary.
Zinbryta	NF	T5 PA	10/1/2017	Daclizumab (Zinbryta), a SQ injection for multiple sclerosis, requires prior authorization.
Taltz	NF	T5 PA	10/1/2017	Ixekizumab (Taltz), a SQ injection for psoriasis, has updated prior authorization criteria.

Formulary Abbreviations: T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand, T4 = Non-Preferred Brand, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, SP = Specialty Drug, QL = Quantity Limit